SynAgile Announces Closing Of $10.4 Million Financing
Published: Aug 24, 2017
WILSON, Wyoming, Aug. 24, 2017 /PRNewswire/ -- SynAgile Corporation (www.SynAgile.com), a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse technology platform, today announced the closing of a $10.4 million round of equity investment. The round was led by affiliates of TAMCAP LLC. The proceeds will be used to conduct the first-in-human, Phase 2 clinical trial of SynAgile's DopaFuse delivery system. The DopaFuse delivery system is the first non-invasive, continuous, levodopa-carbidopa delivery system for the treatment of motor fluctuations associated with Parkinson's disease.
SynAgile is a biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary OraFuse noninvasive, continuous, oral dosing technology, with an initial focus on treating debilitating motor complications in patients with Parkinson's disease using its DopaFuse levodopa-carbidopa delivery system.
OraFuse and DopaFuse are trademarks of SynAgile Corporation.
Ephraim Heller, (510) 788-4435
SOURCE SynAgile Corporation